European approval for Astellas/Theravance's Vibativ in nosocomial pneumonia
This article was originally published in Scrip
Executive Summary
Following a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), Astellas and Theravance have received marketing authorisation from the European Commission for Vibativ (telavancin hydrochloride) for nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).